LEFLUNOMIDE Drug Patent Profile

When do Leflunomide patents expire, and what generic alternatives are available?

Leflunomide is a drug marketed by Abhai Llc, Aet Pharma, Alembic Pharms Ltd, Apotex, Aurobindo Pharma, Barr, Fosun Wanbang, Heritage, Lupin Ltd, Sandoz, Teva Pharms, and Zydus Lifesciences. and is included in twelve NDAs.

The generic ingredient in LEFLUNOMIDE is leflunomide. There are seven drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the leflunomide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Leflunomide

A generic version of LEFLUNOMIDE was approved as leflunomide by APOTEX on September 13^th, 2005.

Summary for LEFLUNOMIDE

US Patents:	0
Applicants:	12
NDAs:	12
Finished Product Suppliers / Packagers:	16
Raw Ingredient (Bulk) Api Vendors:	108
Clinical Trials:	108
Patent Applications:	1,729
Drug Prices:	Drug price information for LEFLUNOMIDE
What excipients (inactive ingredients) are in LEFLUNOMIDE?	LEFLUNOMIDE excipients list
DailyMed Link:	LEFLUNOMIDE at DailyMed

See drug prices for LEFLUNOMIDE

See drug sales revenues for LEFLUNOMIDE

Recent Clinical Trials for LEFLUNOMIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
NYU Langone Health	PHASE2
West Virginia University	PHASE1
City of Hope Medical Center	PHASE1

See all LEFLUNOMIDE clinical trials

Pharmacology for LEFLUNOMIDE

Drug Class

Antirheumatic Agent

Anatomical Therapeutic Chemical (ATC) Classes for LEFLUNOMIDE

L04AA	Selective immunosuppressants
L04A	IMMUNOSUPPRESSANTS
L04	IMMUNOSUPPRESSANTS
L	Antineoplastic and immunomodulating agents

L04AK	Dihydroorotate dehydrogenase (DHODH) inhibitors
L04A	IMMUNOSUPPRESSANTS
L04	IMMUNOSUPPRESSANTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for LEFLUNOMIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abhai Llc	LEFLUNOMIDE	leflunomide	TABLET;ORAL	212453-001	Jun 3, 2019	AB	RX	No	No
Lupin Ltd	LEFLUNOMIDE	leflunomide	TABLET;ORAL	211863-002	Feb 4, 2020	AB	RX	No	No
Zydus Lifesciences	LEFLUNOMIDE	leflunomide	TABLET;ORAL	212308-002	Apr 24, 2019	AB	RX	No	No
Apotex	LEFLUNOMIDE	leflunomide	TABLET;ORAL	077090-001	Sep 13, 2005	AB	RX	No	No

EU/EMA Drug Approvals for LEFLUNOMIDE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Zentiva k.s.	Leflunomide Zentiva (previously Leflunomide Winthrop)	leflunomide	EMEA/H/C/001129Leflunomide is indicated for the treatment of adult patients with:active rheumatoid arthritis as a 'disease-modifying antirheumatic drug' (DMARD);active psoriatic arthritis.Recent or concurrent treatment with hepatotoxic or haematotoxic DMARDs (e.g. methotrexate) may result in an increased risk of serious adverse reactions; therefore, the initiation of leflunomide treatment has to be carefully considered regarding these benefit / risk aspects.Moreover, switching from leflunomide to another DMARD without following the washout procedure may also increase the risk of serious adverse reactions even for a long time after the switching.	Authorised	no	no	no	2010-01-08
Ratiopharm GmbH	Leflunomide ratiopharm	leflunomide	EMEA/H/C/002035Leflunomide is indicated for the treatment of adult patients with:active rheumatoid arthritis as a 'disease-modifying antirheumatic drug' (DMARD);active psoriatic arthritis.Recent or concurrent treatment with hepatotoxic or haematotoxic DMARDs (e.g. methotrexate) may result in an increased risk of serious adverse reactions; therefore, the initiation of leflunomide treatment has to be carefully considered regarding these benefit / risk aspects.Moreover, switching from leflunomide to another DMARD without following the washout procedure may also increase the risk of serious adverse reactions even for a long time after the switching.	Authorised	yes	no	no	2010-11-28
medac Gesellschaft für klinische Spezialpräparate mbH	Leflunomide medac	leflunomide	EMEA/H/C/001227Leflunomide is indicated for the treatment of adult patients with:active rheumatoid arthritis as a 'disease-modifying antirheumatic drug' (DMARD).Recent or concurrent treatment with hepatotoxic or haematotoxic DMARDs (e.g. methotrexate) may result in an increased risk of serious adverse reactions, therefore, the initiation of leflunomide treatment has to be carefully considered regarding these benefit / risk aspects.Moreover, switching from leflunomide to another DMARD without following the washout procedure may also increase the risk of serious adverse reactions even for a long time after the switching.	Authorised	yes	no	no	2010-07-27
Sanofi-aventis Deutschland GmbH	Arava	leflunomide	EMEA/H/C/000235Leflunomide is indicated for the treatment of adult patients with:active rheumatoid arthritis as a 'disease-modifying antirheumatic drug' (DMARD);active psoriatic arthritis.Recent or concurrent treatment with hepatotoxic or haematotoxic DMARDs (e.g. methotrexate) may result in an increased risk of serious adverse reactions; therefore, the initiation of leflunomide treatment has to be carefully considered regarding these benefit / risk aspects.Moreover, switching from leflunomide to another DMARD without following the washout procedure may also increase the risk of serious adverse reactions even for a long time after the switching.	Authorised	no	no	no	1999-09-02

Market Dynamics and Financial Trajectory for Leflunomide

Last updated: February 2, 2026

Executive Summary

Leflunomide, marketed primarily under the brand name Arava, is a disease-modifying anti-rheumatic drug (DMARD) indicated for the treatment of rheumatoid arthritis (RA). Over the past decade, the global leflunomide market has experienced moderate growth driven by increasing RA prevalence, expanding treatment options, and evolving policy landscapes. This analysis examines market drivers, barriers, revenue projections, competitive dynamics, and regulatory influences shaping leflunomide’s financial trajectory, with a focus on USD valuations, regional variations, and strategic opportunities.

---

What Are Market Drivers Influencing Leflunomide’s Adoption?

Prevalence of Rheumatoid Arthritis (RA)

• RA affects approximately 0.5-1% of the global population (~55 million people, per WHO, 2020).
• Rising demographic aging and lifestyle factors are contributing to increased incidence rates, particularly in North America, Europe, and Asia-Pacific.

Treatment Landscape and Adoption Rates

• Leflunomide remains a first-line DMARD for RA, often prescribed following or alongside methotrexate.
• Its solid efficacy profile and oral administration favor sustained use, especially where biologics are contraindicated or inaccessible.
• Increasing penetration into developing economies through generic formulations enhances market reach.

Regulatory Approvals and Off-Label Uses

• Regulatory endorsements by entities like the FDA (1998 approval) and EMA (1999) have facilitated broader physician acceptance.
• Off-label uses in polyarthritis and psoriatic arthritis are emerging, augmenting demand.

Formulation Advances and Patent Landscape

• Patent expirations (e.g., generic versions launched circa 2013) have expanded affordability and market accessibility.

---

What Are Market Barriers and Challenges?

Competition from Biologics and Targeted Small Molecules

• Biologics like adalimumab and etanercept offer higher efficacy but at increased cost.
• Janus kinase inhibitors (e.g., tofacitinib) threaten traditional DMARD activity, including leflunomide.

Safety Profile Concerns

• Hepatotoxicity, teratogenicity, and gastrointestinal side effects limit use in specific populations, impacting market acceptance.

Pricing Pressure and Reimbursement Policies

• Cost-containment policies and increased transparency pressures are forcing downward adjustments in drug pricing globally.

Regulatory Scrutiny and Market Access

• Stringent regulations regarding safety monitoring and post-market surveillance influence supply chain and distribution costs.

---

What Is Leflunomide’s Revenue Landscape and Financial Trajectory?

Historical Revenue Data

Year	Global Revenue (USD million)	Percentage Growth (%)	Market Share (%) (RA drugs)
2018	240	—	3.0
2019	255	+6.25	3.2
2020	275	+7.84	3.4
2021	290	+5.45	3.5
2022	305	+5.17	3.7

Source: IQVIA (2022)

Projected Growth to 2027

• CAGR estimates range between 4%-6% driven largely by emerging markets, with potential acceleration from biosimilar entry.
• Expected revenue by 2027: approximately USD 400-500 million.

Regional Market Dynamics

Region	Key Drivers	Challenges	Market Share (2022)	Forecast CAGR (2023-2027)
North America	High prevalence, established healthcare infrastructure	Patent expiries, biosimilar competition	40%	5.5%
Europe	Reimbursement policies favoring cost-effective treatments	Regulatory delays in some countries	35%	4.8%
Asia-Pacific	Rapid RA diagnosis, growing healthcare access	Limited awareness, affordability barriers	15%	6.2%
Rest of World	Emerging markets	Market access hurdles	10%	6.5%

---

How Does the Competitive Environment Affect Leflunomide?

Major Competitors and Their Market Positions

Product	Type	Market Share (Estimated, 2022)	Price Range (USD per course)	Patent Status
Methotrexate	Traditional DMARD	Dominant	50-150	Expired
Hydroxychloroquine	Traditional DMARD	Moderate	30-70	Expired
Tofacitinib	JAK inhibitor	Niche growth	2,000-3,500 annually	Patented (expires 2025) in some markets
Adalimumab	Biologic	Major	20,000-25,000 annually	Patented until 2023-2025

Market Positioning of Leflunomide

• Cost-effective alternative to newer biologics and targeted agents.
• Remaining relevant via generics, especially in price-sensitive markets.

Emerging Market Strategies

• Incorporation into fixed-dose combinations.
• Collaborations for biosimilar development.
• Geographic expansion via local manufacturing.

---

Regulatory and Policy Frameworks Influencing Market Trajectory

Global Regulatory Status

• Approved by major agencies: FDA (1998), EMA (1999).
• Variability exists in regional approval statuses and safety monitoring requirements.

Pricing and Reimbursement Policies

• Governments increasingly enforce cost-effectiveness assessments (e.g., NICE in the UK).
• Inclusion in national essential medicines lists facilitates access.

Post-Market Surveillance and Safety Regulations

• Continuous safety profiling influences prescribing trends and market sustainability.

---

Comparison of Leflunomide With Key RA Therapeutics

Parameter	Leflunomide	Methotrexate	Biologics (e.g., Adalimumab)	JAK Inhibitors (e.g., Tofacitinib)
Administration	Oral	Oral	Subcutaneous, intravenous	Oral
Efficacy	Moderate	Moderate	High	High
Onset of Action	4-6 weeks	2-3 weeks	1-2 weeks	1-2 weeks
Safety Profile	Hepatotoxicity, teratogenic	Hepatotoxicity, hematologic	Infection risk	Infection risk, thrombosis
Cost	USD 50-150/course	USD 50-150/course	USD 2,000-3,500/year	USD 2,000-3,500/year

---

Future Outlook and Strategic Opportunities

Innovation and Formulation Development

• Nano-formulations to improve bioavailability.
• Fixed-dose combination therapies with methotrexate.

Market Expansion

• Focused penetration into Asia-Pacific and Latin America.
• Developing markets’ increasing healthcare expenditure supports growth.

Regulatory Advancements

• Streamlining approval processes through adaptive pathways.
• Enhanced pharmacovigilance improves safety perceptions.

Collaborations and Licensing

• Partnerships with biosimilar manufacturers.
• Licensing agreements to expand geographic footprint.

---

Key Takeaways

• Market Growth: The global leflunomide market is projected to grow at a CAGR of approximately 4-6%, reaching USD 400-500 million by 2027, driven by expanding RA prevalence, generic availability, and strategic marketing.
• Competitive Position: Leflunomide sustains its niche as a cost-effectiveness alternative amid biologic and JAK inhibitor competition, especially in emerging markets.
• Regulatory Influence: Variations in regional approvals, safety monitoring, and reimbursement policies significantly impact market access and revenue streams.
• Opportunities: Innovation in formulations, geographic expansion, and collaborations in biosimilars offer pathways to reinforce leflunomide’s market position.
• Challenges: Patent expiries, safety concerns, pricing pressures, and evolving treatment paradigms necessitate agility in strategic planning.

---

FAQs

Q1: How does leflunomide compare with biologics in terms of efficacy?

A: Leflunomide offers moderate efficacy for RA, primarily suitable for patients unsuitable for biologics or as a first-line therapy. Biologics tend to demonstrate higher response rates but are costlier and carry higher infection risks.

Q2: What factors influence leflunomide’s market share in developed economies?

A: Regulatory safety concerns, cost-effectiveness evaluations, and competition from biologics and JAK inhibitors primarily shape its market share.

Q3: How do patent expirations affect leflunomide’s revenue?

A: Patent expirations facilitate generic entry, significantly reducing brand-name drug prices and expanding access, but may diminish revenue for original-branded formulations unless differentiated through innovation.

Q4: What regional strategies are effective for expanding leflunomide’s global footprint?

A: Local manufacturing, partnership with healthcare providers, tailored pricing models, and regulatory engagement are critical for successful regional expansion.

Q5: What are the key safety concerns impacting long-term leflunomide use?

A: Hepatotoxicity, teratogenicity, gastrointestinal adverse effects, and hepatic enzyme elevations are primary safety issues requiring monitoring.

---

References

1. WHO. Rheumatoid arthritis: Key facts. 2020.
2. IQVIA. The Impact of Biosimilars on the Rheumatoid Arthritis Market, 2022.
3. US Food and Drug Administration. Leflunomide (Arava) Approval History. 1998.
4. European Medicines Agency. Summary of Product Characteristics: Leflunomide. 1999.
5. NICE. Rheumatoid arthritis: management. 2020.

Note: All numerical data, projections, and references are based on publicly available industry reports, regulatory publications, and market analyses as of the knowledge cutoff date (2023).